Examining AnaptysBio's recent Phase 2b data on Rosnilimab for the treatment of rheumatoid arthritis (RA)

Executed on:Jul 3, 2025 9:30 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Rowan Diagnostic Clinic (Private Practice)Rheumatologist at Rowan Diagnostic Clinic in North Carolina; fellowship trained at University of Massachusetts Medical Center.
Manages 250 patients with rheumatoid arthritis,
Familiar with the rosnilimab phase 2B trial results and can speak to its benefits in the future RA landscape

Interview Goal

This conversation will focus on AnaptysBio investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA). We will discuss the global 424-patient Phase 2b trial.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.